SWI/SNF complex antagonist associated with prostate cancer 1Genealiases: LINC00913 · PCAT11 · PCAT114
Q-omics provides the consensus-scored SCHLAP1 profile across patient tissues and cancer cell-line models. SCHLAP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SCHLAP1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SCHLAP1 RNA expression shows 7,038 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where SCHLAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCHLAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCHLAP1 survival associations across molecular data types. SCHLAP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCHLAP1 RNA expression–survival associations across cancer types. High SCHLAP1 expression shows unfavorable associations in KIRC, HNSC, BRCA, COAD, KICH and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SCHLAP1 RNA expression.
This table summarizes SCHLAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCHLAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCHLAP1 shows lower tumor expression in KIRC, KICH, THCA and KIRP and higher tumor expression in HNSC and PRAD. The KIRC box plot shows higher SCHLAP1 RNA expression in normal versus tumor tissue (log2 FC = −0.575, t-test p < 0.001).
This table shows molecular features associated with SCHLAP1 in patient tissues and cancer cell lines. In patient samples, SCHLAP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
